Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

China, licensing agreement with 3SBio, granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

On May 19, Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese biopharmaceutical firm 3SBio Inc.

ImmuCell shares ICCC ended up $5.14, or 121 percent, at $9.39 after climbing as high as $9.65 earlier in the session. Pfizer Inc PFE shares climbed 98 cents, or 3.9 percent, to $25.95. Show ...

Pfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental Covid-19 pill. The agreement with the Medicines Patent Pool, a United Nations-backed public ...

In a regulatory filing issued by Targacept Monday, Catalyst notified company officials Wednesday that Pfizer would end its June 2009 licensing agreement with Wyeth.

Written by Zacks Equity Research for Zacks -> Pharmaceutical giant Pfizer Inc. PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental cancer drug, SSGJ-707.